AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
November 5, 2019 7:22 AM ESTMizuho Securities analyst Difei Yang reiterated a Buy rating and $30.00 price target on Evolus (NASDAQ: EOLS) following the company's 3Q earnings report. Both revenue and EPS came in above consensus estimates, driven by strong sales from Jeuveau in the... More
Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat
November 4, 2019 7:09 AM ESTEvolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.
This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More
